Dr. Janet Peper-Gabriel

Dr. Janet Peper-Gabriel is Head of Preclinical Development at Plectonic Biotech, leading the advancement of DNA nanotechnology-based T-cell engagers from discovery to clinical testing. With over 14 years of experience in cancer immunotherapies, she has successfully overseen more than 20 preclinical and clinical projects and played a key role in translating 4-1BB bispecific cancer therapeutics to the clinic. An expert in preclinical drug development, she has implemented high-throughput screening platforms and cutting-edge technologies, ensuring regulatory alignment. Janet earned her Ph.D. in Cancer Immunology from Eberhard Karls University Tübingen, focusing on peptide-based anti-tumor vaccination strategies.